Q2 2016 · —
Revenue—
Net Income-$6.06M-$6.06M no prior Q2 2015 on fileN/M vs Q1 2016
EPS Diluted-$25.30-$25.30 no prior Q2 2015 on fileN/M vs Q1 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q2 2015 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR